Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer (BAYRY) is running ACO-REAL, a non-interventional study that tracks real-world use of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The goal is to understand who receives the drug, how it is used in everyday care, and how it affects heart health, daily function, and safety over time.
The study looks at acoramidis, an oral drug (also known as BEYONTTRA) designed to stabilize the transthyretin protein. By doing so, it aims to slow or prevent harmful deposits in the heart, reduce stiffness, and help manage symptoms in people with both wild-type and hereditary ATTR-CM.
ACO-REAL is observational and cohort-based, so doctors and patients follow normal care without randomization or blinding. Researchers simply collect data prospectively from up to 2,000 adults across about 20 European countries who start acoramidis as part of their usual treatment.
The study was first submitted on 6 Oct 2025, marking the start of organized data collection in routine practice. The latest update on 30 Mar 2026 signals that recruitment and protocol details are current, with primary and final completion dates expected to align with longer-term follow-up once enough real-world outcomes are captured.
For investors, this update reinforces Bayer’s push to build a durable franchise in ATTR-CM on top of prior trial success and U.S./EU approval. Positive real-world data could support broader physician uptake, better reimbursement negotiations, and sustained revenue, while any safety or effectiveness issues could weigh on sentiment and the stock.
Competition in ATTR-CM includes tafamidis and emerging agents from large pharma, so strong real-world outcomes may help Bayer defend or grow share in a crowded market. The ACO-REAL update suggests Bayer is investing in evidence that payers and cardiologists increasingly demand, which could be a modest long-term catalyst if data confirm clinical and economic value.
The ACO-REAL study of acoramidis in routine practice is active and being updated, with more details available on the ClinicalTrials portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.